Sanofi’s 340B Rebate Model: A Joint Effort to Reform Drug Pricing Practices

By Rene Pretorius

November 29, 2024

How can a rebate model reshape the 340B Drug Pricing Program to address inefficiencies and abuses? Sanofi has introduced a 340B rebate model as a potential solution to long-standing challenges within the program. The 340B Program enables eligible hospitals to purchase outpatient drugs at discounted prices, contingent upon serving a minimum percentage of low-income Medicare and Medicaid patients. However, recent changes proposed by pharmaceutical companies like Eli Lilly and Johnson & Johnson—favoring rebates over point-of-purchase discounts—have sparked debates and drawn scrutiny from federal regulators. Sanofi’s initiative follows those of Eli Lilly and Johnson & Johnson with the aim to refine the program by tackling its inefficiencies.

Sanofi’s 340B Rebate Model

Sanofi has proposed a new 340B rebate model specifically to combat problems such as duplicate discounts and diversion. These practices have been criticized for benefiting entities that do not serve the vulnerable patients the program is meant to assist. By focusing on these issues, Sanofi’s 340B rebate model represents a significant step towards improved efficiency in the pharmaceutical sector.

Alignment with J&J and Eli Lilly

Sanofi’s initiative mirrors that of other pharmaceutical giants like Johnson & Johnson (J&J) and Eli Lilly. Both these companies have proposed their own rebate models addressing similar concerns. Here are some key points of alignment:

  • Addressing Abuse

All three companies (Sanofi, J&J, and Eli Lilly) are united in their focus on core issues: duplicate discounts and diversion. These practices lead to scenarios where entities claim rebates on prescriptions purchased at discounted 340B prices or provide 340B medicines to ineligible patients. With their rebate models, these Companies seek to eliminate these abuses and ensure that the program’s savings are directed towards the vulnerable populations it is designed to help.

  • Mechanism of the Model

Under Sanofi’s Credit Model, covered entities submit claims for 340B-eligible medicines through the 340B rebate model. This will enable Sanofi to pay the difference between the 340B price and the list price. This approach mirrors the models proposed by J&J and Eli Lilly, which also involve direct payment or rebate mechanisms. These models require entities to supply specific data confirming 340B eligibility, thus enhancing transparency and oversight within the system.

Industry-Wide Initiative

By aligning with J&J and Eli Lilly in proposing these rebate models, Sanofi is taking part in an industry-wide initiative to reform the 340B program. This coordinated effort demonstrates a broader commitment among pharmaceutical companies to ensure that safety net programs operate effectively and provide affordable care to vulnerable patients, rather than benefiting intermediaries.

Despite the positive intentions behind Sanofi’s 340B rebate model and those of its peers, criticisms have emerged from some 340B providers. These critics argue that the models could disrupt patient care and create additional administrative burdens. Sanofi and other companies assert that they design their rebate models to uphold the original intent of the 340B program. They also aim to introduce necessary checks and balances to ensure the program operates efficiently.

In summary, Sanofi’s 340B rebate model aligns closely with the initiatives of J&J and Eli Lilly. Its intent is to eliminate abuses, enhance transparency, and ensure that the program benefits the intended patient populations. This collective action highlights the industry’s effort to reform and strengthen the 340B program. It underscores its vital role in healthcare.

Reference url

Recent Posts

prior authorization reforms
     

Streamlining Prior Authorization Reforms: Impacts and Insights for HEOR

🚀 Are prior authorizations stalling care delivery in the U.S. healthcare system?

The HHS has launched an ambitious collaboration with major insurers to reform prior authorization processes across Medicare Advantage, Medicaid, and commercial plans. With a goal to standardize submissions by 2027 and significantly reduce requirements by 2026, this initiative promises to accelerate care decisions and enhance transparency.

Dive into the details of these pivotal reforms and discover their potential to streamline healthcare and improve patient outcomes.

#SyenzaNews #HealthcareInnovation #healthcare #healthcarepolicy

private health funding
    

Private Health Funding Under South Africa’s National Health Insurance Act

🚀 Update on NHI in South Africa.

In their insightful article, Solanki et al. discuss the complexities of private health funding amidst the nation’s National Health Insurance Act. They discuss two key scenarios: a passive approach that risks the sustainability of the private sector and an active reform strategy that could ensure a smoother transition to universal coverage.

Curious about how these strategies could reshape healthcare access and costs in South Africa? Don’t miss out on this critical analysis!

#SyenzaNews #HealthEconomics #HealthcarePolicy

drug price transparency
     

Impending Net Drug Price Transparency Regulation in the U.S.

💡 Are you ready for a potential game-changer in drug pricing transparency?

CMS Administrator Mehmet Oz has hinted at a new rule aimed at enforcing stricter disclosures for drug prices, requiring healthcare companies to reveal actual transaction costs. This could reshape how price transparency is managed across the industry and challenge pharmacy benefit managers to rethink rebate practices.

Curious about how this will impact healthcare economics and what it means for drug affordability? Dive into the article for all the insights!

#SyenzaNews #healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.